TAILIEUCHUNG - Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review

Hepatitis C virus clearance is expected in more than 95% of patients treated with direct-acting antivirals (DAAs). However, an extensive debate about the impact of DAAs on the development of hepatocellular carcinoma (HCC) is currently ongoing. This review aimed to explore currently available evidence about the relationship between DAAs and HCC development. The American studies and some European studies clearly showed no relation, while the Japanese and Egyptian studies and the other European studies showed an increased risk of developing HCC after DAA exposure. These conflicting results may be due to geographical and ethnic variations and differences in the design and inclusion criteria among the studies. After reviewing the data from these different studies, it seems that some patients are at increased risk of developing HCC after DAA exposure. Identifying those at increased risk is very important for the management of HCC in light of the potentially major consequences of HCC for the patients’ quality of life and the subsequent major burden imposed on healthcare resources. | Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review

• Y khoa - Dược
• Hepatocellular carcinoma
• Hepatitis C virus
• Direct acting antiviral agents
• Treating chronic hepatitis C infection
• Hepatocellular carcinoma
• Summary of doctoral thesis in medicine
• Clinical of hepatocellular carcinoma and paraclinical
• Histopathology of hepatocellular carcinoma
• Immunohistochemical characteristics of hepatocellular carcinoma
• Portal vein thrombosis
• Involving factors in pateins with PVT
• BMC Cancer
• Hepatocellular proliferation
• P53 ubiquitination
• Hepatocellular cells
• Anti tumor role
• TNF α 308 polymorphism
• Hepatocellular carcinoma risk
• 102 healthy blood donors
• Chronic hepatitis B virus
• Molecular markers
• Prognostic system
• Associated HCV infection
• Circulating miRNAs
• Viral etiology
• Stereotactic body radiation therapy
• Small hepatocellular carcinoma
• Radiofrequency ablation
• Small ubiquitin related modifier
• HBV associated hepatocellular carcinoma
• HEK 293T cells
• Systemic therapy
• Systemic therapy for hepatocellular carcinoma
• Adjuvant regimens for HCC
• Sorafenib was first approved
• Prolong survival of the patients
• Barcelona Classification
• Non alcoholic fatty liver disease
• Visceral fat
• Metabolic syndrome
• Journal of Chemistry
• 7 Ethyl 10 hydroxycamptothecin
• Anticancer drug irinotecan
• Anticancer agent against HCC
• Hepatocellular carcinoma (HCC)
• Clinical of patients
• Laboratory characteristics
• Prognosis of patients with hepatocellular carcinoma
• Clinical presentation
• Prognostic model
• Real time PCR HRM
• Molecular genotyping assay
• Reaction high resolution melting
• Transcatheter arterial chemoembolization
• Clinical trial
• Advanced hepatocellular carcinoma
• Delayed reaction
• High fever
• Ectopic hepatocellular carcinoma
• Western blot
• Carcinoma remains unclear
• Quantitative reverse transcription PCR
• Combined hepatocellular
• Progenitor cell
• Hippo pathway
• Metallothionein 1H
• Wnt/β catenin
• Hepatocellular cancer
• Including hepatocellular cancer
• Scientific reports
• scientific research
• Structural biochemistry
• phosphatase
• medical analysis
• Epidemiology
• Risk Factors
• Surgical Treatment
• Liver Metastases
• Tạp chí khoa học
• The short term outcome of radiofrequency ablation
• Hepatocellular carcinoma at Binh Dan hospital
• Binh Dan hospital
• Short term outcome of radiofrequency ablation
• MicroRNAs 122
• Alpha fetoprotein
• Computed tomography
• Magnetic resonance imaging
• Gamma carboxy prothrombin
• Complete ablation rate
• Tumor progression
• Intra nodular
• Peripheral enhancement
• Diagnostic accuracy of PIVKA II
• Combination of both in diagnosis
• Vitamin K absence